Arends MJ, Morris RG and Wyllie AH (1990) Apoptosis. The role of the endonuclease. Am J Pathol136: 593–608 CAS Google Scholar
Asou Y, Rittling SR, Yoshitake H, Denhardt DT and Noda M (1999) Osteopontin-deficient bone is defective in angiogenesis, osteoclast-recruitment and ectopic resorption. Proceedings from the 21st Annual Meeting of the American Society for Bone and Mineral Research,
Behrend EI, Craig AM, Wilson SM, Denhardt DT and Chambers AF (1994) Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res54: 832–837 CAS Google Scholar
Behrend EI, Craig AM, Wilson SM, Denhardt DT and Chambers AF (1995) Expression of antisense osteopontin RNA in metastatic mouse fibroblasts is associated with reduced malignancy. Ann N Y Acad Sci760: 299–301 ArticleCAS Google Scholar
Bloomfield DJ (1998) Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol16: 1218–1225 ArticleCAS Google Scholar
Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD and Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res57: 3890–3894 CAS Google Scholar
Brown LF, Papadopoulos Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF and Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol145: 610–623 CAS Google Scholar
Butle WT (1989) The nature and significance of osteopontin. Connect Tissue Res23: 123–136 Article Google Scholar
Chan YL, Gutell R, Noller HF and Wool IG (1984) The nucleotide sequence of a rat 18 S ribosomal ribonucleic acid gene and a proposal for the secondary structure of 18 S ribosomal ribonucleic acid. J Biol Chem259: 224–230 CAS Google Scholar
Chikatsu N, Takeuchi Y, Tamura Y, Fukumoto S, Yano K, Tsuda E, Ogata E and Fujita T (2000) Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun267: 632–637 ArticleCAS Google Scholar
Coleman RE and Purohit OP (1993) Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev19: 79–103 ArticleCAS Google Scholar
Craig AM, Nemir M, Mukherjee BB, Chambers AF and Denhardt DT (1988) Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun157: 166–173 ArticleCAS Google Scholar
Denhardt DT and Guo X (1993) Osteopontin: a protein with diverse functions. Faseb J7: 1475–1482 ArticleCAS Google Scholar
Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med339: 357–363 ArticleCAS Google Scholar
Dodds RA, Connor JR, James IE, Rykaczewski EL, Appelbaum E, Dul E and Gowen M (1995) Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone. J Bone Miner Res10: 1666–1680 ArticleCAS Google Scholar
Evans CE and Braidman IP (1994) Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner26: 95–107 ArticleCAS Google Scholar
Flanagan AM and Chambers TJ (1989) Dichloromethylenebisphosphonate (C12MBP) inhibits bone resorption through injury to osteoclasts that resorb C12MBP-coated bone. Bone Miner6: 33–43 ArticleCAS Google Scholar
Fleisch H (1993) New bisphosphonates in osteoporosis. Osteoporos Int3 Suppl 2: S15–22 ArticleCAS Google Scholar
Galasko CS (1976) Mechanisms of bone destruction in the development of skeletal metastases. Nature263: 507–508 ArticleCAS Google Scholar
García Moreno C, Serrano S, Nacher M, Farré M, A, DI, Mariñoso, M, A, DI Carbonell J, Mellibovsky L, Nogués X, Ballester J and Aubía J (1998) Effect of alendronate on cultured normal human osteoblasts. Bone22: 233–239 Article Google Scholar
Gardner HA, Berse B and Senger DR (1994) Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat 1 fibroblasts. Oncogene9: 2321–2326 CAS Google Scholar
Goziotis A, Sukhu B, Torontali M, Dowhaniuk M and Tenenbaum HC (1995) Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone16: 317S–327S ArticleCAS Google Scholar
Helfrich MH, Nesbitt SA, Dorey EL and Horton MA (1992) Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin. J Bone Miner Res7: 335–343 ArticleCAS Google Scholar
Horwood NJ, Elliott J, Martin TJ and Gillespie MT (1998) Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology139: 4743–4746 ArticleCAS Google Scholar
Jilka RL, Weinstein RS, Bellido T, Parfitt AM and Manolagas SC (1998) Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res13: 793–802 ArticleCAS Google Scholar
Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JMW, Niforas P, Ng KW, Martin TJ and Gillespie MT (1999) Localization of RANKL (Receptor Activator of NFKB Ligand) mRNA and Protein in Skeletal and Extraskeletal Tissues. Bone25: 525–534 ArticleCAS Google Scholar
Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G and Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res13: 581–589 ArticleCAS Google Scholar
Majeska RJ, Port M and Einhorn TA (1993) Attachment to extracellular matrix molecules by cells differing in the expression of osteoblastic traits. J Bone Miner Res8: 277–289 ArticleCAS Google Scholar
Martin TJ, Ingleton PM, Underwood JC, Michelangeli VP, Hunt NH and Melick RA (1976) Parathyroid hormone-responsive adenylate cyclase in induced transplantable osteogenic rat sarcoma. Nature260: 436–438 ArticleCAS Google Scholar
Merry K, Dodds R, Littlewood A and Gowen M (1993) Expression of osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone. J Cell Sci104: 1013–1020 CAS Google Scholar
Oldberg A, Franzén A and Heinegård D (1986) Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA83: 8819–8823 ArticleCAS Google Scholar
Orr FW, Sanchez-Sweatman OH, Kostenuik P and Singh G (1995) Tumor-bone interactions in skeletal metastasis. Clin Orthop, 19–33
Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC and Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest104: 1363–1374 ArticleCAS Google Scholar
Reinholt FP, Hultenby K, Oldberg A and Heinegard D (1990) Osteopontin – a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA87: 4473–4475 ArticleCAS Google Scholar
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J and Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer88: 2989–2994 Article Google Scholar
Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, Mintz KA, Robey PG, Teitelbaum SL and Cheresh DA (1993) Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem268: 9901–9907. CAS Google Scholar
Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C and Fleisch HA (1999) The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res14: 53–65 ArticleCAS Google Scholar
Sahni M, Guenther HL, Fleisch H, Collin P and Martin TJ (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest91: 2004–2011 ArticleCAS Google Scholar
Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E and Rodan GA (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest88: 2095–2105 ArticleCAS Google Scholar
Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer82: 1459–1468 ArticleCAS Google Scholar
Shipman CM, Rogers MJ, Apperley JF, Russell RG and Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol98: 665–672 ArticleCAS Google Scholar
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P and Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell89: 309–319 ArticleCAS Google Scholar
Sodek J, Chen J, Nagata T, Kasugai S, Todescan R Jr, Li IW and Kim RH (1995) Regulation of osteopontin expression in osteoblasts. Ann N Y Acad Sci760: 223–241 ArticleCAS Google Scholar
Tan PL, Katz JM, Ames R, Caughey DE, Gray HD, Ibbertson HK and Watson JD (1988) Aminobisphosphonate inhibition of interleukin-1-induced bone resorption in mouse calvariae. Arthritis Rheum31: 762–768 ArticleCAS Google Scholar
Thiébaud D, Leyvraz S, von Fliedner V, Perey L, Cornu P, Thiébaud S and Burckhardt P (1991) Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer27: 37–41 Article Google Scholar
van der Pluijm G, Vloedgraven H, van Beek E, van der Wee- Pals L, C Lö and Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest98: 698–705 ArticleCAS Google Scholar
Vitté C, Fleisch H and Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology137: 2324–2333 Article Google Scholar
Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, 3rd Frankel WN, Lee SY and Choi Y (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem272: 25190–25194 ArticleCAS Google Scholar
Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T and Higashio K (1998a) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology139: 1329–1337 Article Google Scholar
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N and Suda T (1998b) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA95: 3597–3602 ArticleCAS Google Scholar
Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD and Nishikawa S (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature345: 442–444 ArticleCAS Google Scholar
Yu X, Scholler J and Foged NT (1996) Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone19: 339–345 ArticleCAS Google Scholar